Skip to Content

Dipyridamole Pregnancy and Breastfeeding Warnings

Dipyridamole is also known as: Persantine, Persantine IV

Dipyridamole Pregnancy Warnings

In one study, therapy with dipyridamole 300 mg and aspirin 150 mg per day was initiated at 13 weeks' gestation in 52 pregnant patients at high risk for preeclampsia and fetal growth retardation. Compared to 50 control patients, women treated with dipyridamole had a lower incidence of preeclampsia, fetal loss, and fetal growth retardation. Abnormal bleeding was absent in both mother and neonate in all cases. In another study, 24 women (30 pregnancies) with a history of fetal growth retardation and placental infarction in previous pregnancies were treated with aspirin 1 to 1.6 mg/kg and dipyridamole 225 mg per day from 16 to 34 weeks' gestation. A control group consisted of 24 women (27 pregnancies) with a similar history. Fetal growth retardation occurred in 13% of pregnancies in the treated group compared to 61% of pregnancies in the control group. No adverse maternal or fetal effects could be attributed to dipyridamole or aspirin. Similar findings have been documented by other studies and case reports. Data on the safety of dipyridamole during the first trimester are limited.

Dipyridamole has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of teratogenicity. Dipyridamole has been given throughout pregnancy in patients requiring anticoagulation for prosthetic heart valve as well as for the prevention of preeclampsia and intrauterine growth retardation. No malformations have been reported associated with perinatal use of dipyridamole. Dipyridamole should only be given during pregnancy when need has been clearly established.

See references

Dipyridamole Breastfeeding Warnings

Dipyridamole is excreted into human milk in small amounts. There are no reports of adverse events in infants secondary to breast-feeding during dipyridamole administration. The manufacturer recommends that caution be used when giving dipyridamole to nursing women.

See references

References for pregnancy information

  1. "Product Information. Persantine (dipyridamole)." Boehringer-Ingelheim, Ridgefield, CT.
  2. Wallenburg HC, Rotmans N "Prevention of recurrent idiopathic fetal growth retardation by low- dose aspirin and dipyridamole." Am J Obstet Gynecol 157 (1987): 1230-5
  3. Beaufils M, Uzan S, Donsimoni R, Colau JC "Prevention of pre-eclampsia by early antiplatelet therapy." Lancet 1 (1985): 840-2
  4. Biale Y, Cantor A, Lewenthal H, Gueron M "The course of pregnancy in patients with artificial heart valves ;treated with dipyridamole." Int J Gynaecol Obstet 18 (1980): 128-32
  5. Snethlage W, Ten Cate JW "Thrombocythaemia and recurrent late abortions: normal outcome of pregnancies after antiaggregatory treatment. Case report." Br J Obstet Gynaecol 93 (1986): 386-8
  6. Ahmad R, Rajah SM, Mearns AJ, Deverall PB "Dipyridamole in successful management of pregnant woman with prosthetic heart valve ." Lancet 2 (1976): 1414-5
  7. Wallenburg HC, Rotmans N "Prophylactic low-dose aspirin and dipyridamole in pregnancy ." Lancet 1 (1988): 939

References for breastfeeding information

  1. "Product Information. Persantine (dipyridamole)." Boehringer-Ingelheim, Ridgefield, CT.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.